Olanzapine

Generic Name
Olanzapine
Brand Names
Lybalvi, Olazax, Symbyax, Zalasta, Zypadhera, Zyprexa, Olanzapine Glenmark Europe, Olanzapine Apotex, Olanzapine Teva, Olazax Disperzi, Olanzapine Mylan, Zyprexa Velotab, Olanzapine Glenmark
Drug Type
Small Molecule
Chemical Formula
C17H20N4S
CAS Number
132539-06-1
Unique Ingredient Identifier
N7U69T4SZR
Background

Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.

Indication

Olanzapine was initially used orally and intramuscularly for the chronic treatment of schizophrenia in patients over 13 years old and other psychiatric disorders such as bipolar I disorder including mixed or manic episodes.

Olanzapine is also indicated, in combination with lithium or valproate for the short-term treatment of acute manic or mixed episodes associated with bipolar I disorder in adults.

As well, olanzapine is indicated, in combination with fluoxetine for the treatment of episodes of depression associated with bipolar disorder type 1 and treatment-resistant depression in patients over 10 years old.

Olanzapine is also approved for the management of psychomotor agitation associated with schizophrenia and bipolar I mania.

Schizophrenia is a complex biochemical brain disorder that affects the person's ability to differentiate reality. It is usually observed as the presence of delusions, hallucinations, social withdrawal and disturbed thinking.

Bipolar disorder is a mental health condition defined by periods of extreme mood disturbances. It is categorized in different types from which type 1 is known to involve episodes of severe mania and often depression while type 2 presents less severe forms of mania.

Olanzapine is also indicated in combination with samidorphan for the treatment of bipolar I disorder, either as an adjunct to lithium or valproate or as monotherapy for the acute treatment of manic or mixed episodes or as maintenance therapy, and for the treatment of schizophrenia in adults.

Associated Conditions
Acute Agitation, Bipolar 1 Disorder, Bipolar Disorder With Manic or Mixed Episodes, Delirium, Delusional Parasitosis, Depressive Episodes, Gilles de la Tourette's Syndrome, Major depressive disorder, recurrent episode, Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
Associated Therapies
-

Efficacy of Olanzapine Monotherapy for Treatment Bipolar Ⅰ Depression

First Posted Date
2011-02-25
Last Posted Date
2011-02-25
Lead Sponsor
China Medical University, China
Target Recruit Count
68
Registration Number
NCT01303601
Locations
🇨🇳

Department of Psychiatry, the First Hospital of China Medical University, Shenyang, Liaoning, China

Risperidone vs. Olanzapine as add-on Treatment in Treatment Resistant Depression

First Posted Date
2011-01-25
Last Posted Date
2011-01-25
Lead Sponsor
Sunnybrook Health Sciences Centre
Target Recruit Count
42
Registration Number
NCT01282632
Locations
🇨🇦

Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

First Posted Date
2010-11-04
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
301
Registration Number
NCT01234779

Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-11-04
Last Posted Date
2015-04-03
Lead Sponsor
University of North Carolina, Chapel Hill
Target Recruit Count
34
Registration Number
NCT01234454
Locations
🇺🇸

Unc Psychiatry, Chapel Hill, North Carolina, United States

Antipsychotics and Gene Expression in Soft Tissues

First Posted Date
2010-08-20
Last Posted Date
2017-03-23
Lead Sponsor
Medical University of Vienna
Target Recruit Count
16
Registration Number
NCT01185743
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents

Phase 3
Terminated
Conditions
Interventions
First Posted Date
2010-08-19
Last Posted Date
2014-09-04
Lead Sponsor
Children's Hospital of Eastern Ontario
Target Recruit Count
38
Registration Number
NCT01184443
Locations
🇨🇦

Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2010-07-27
Last Posted Date
2018-06-29
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
152
Registration Number
NCT01170117
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

🇺🇸

Weill Cornell Medical Center, White Plains, New York, United States

🇺🇸

New York State Psychiatric Institute, New York, New York, United States

and more 2 locations

Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia

First Posted Date
2010-07-16
Last Posted Date
2015-06-22
Lead Sponsor
University of Bremen
Target Recruit Count
149
Registration Number
NCT01164059
Locations
🇩🇪

Klinikum Bremen-Ost gGmbH, Bremen, Germany

🇩🇪

Rheinische Kliniken Düsseldorf der Heinrich-Heine-Universität, Düsseldorf, Germany

🇩🇪

Privat-Nerven-Klinik Dr. med. Kurt Fontheim, Liebenburg, Germany

and more 15 locations

Effect of Atypical Antipsychotic Drugs Olanzapine and Amisulpride on Glucose Metabolism

First Posted Date
2010-07-13
Last Posted Date
2010-08-03
Lead Sponsor
Central Institute of Mental Health, Mannheim
Target Recruit Count
10
Registration Number
NCT01160991
Locations
🇩🇪

Central Institute of Mental Health, Mannheim, Germany

© Copyright 2024. All Rights Reserved by MedPath